Imagion Biosystems Limited has announced Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 31 March, 2018.
Read Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)